Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the working party on hospital-acquired pneumonia of the british society for antimicrobial chemotherapy

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 1, 2008, Pages 5-34

  Masterton, Robert G ^a   Galloway, A ^b   French, G ^c   Street, M ^d   Armstrong, J ^e   Brown, E ^f   Cleverley, J ^g   Dilworth, P ^g   Fry, C ^h   Gascoigne, A D ^b   Knox, Alan ⁱ   Nathwani, Dilip ^j   Spencer, Robert ^k   Wilcox, Mark ^l  

^a CROSSHOUSE HOSPITAL   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^e Northern and Yorkshire Regional Training Scheme   (United Kingdom)

^f FRENCHAY HOSPITAL   (United Kingdom)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h Department of Health ^*  (United Kingdom)

ⁱ NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^j UNIVERSITY OF DUNDEE   (United Kingdom)

^k PUBLIC HEALTH ENGLAND   (United Kingdom)

^l UNIVERSITY OF LEEDS   (United Kingdom)

more..

Author keywords

Antimicrobial treatment; Diagnosis; Evidence based guidelines; Healthcare associated pneumonia; Hospital acquired pneumonia; Prevention

Indexed keywords

ACTIVATED PROTEIN C; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZLOCILLIN; CARBAPENEM; CARBENICILLIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMIPENEM; INFLUENZA VACCINE; LINEZOLID; MEROPENEM; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; TEICOPLANIN; TICARCILLIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ADJUVANT THERAPY; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTIFICIAL VENTILATION; ASPERGILLOSIS; ASPERGILLUS; BLOOD CULTURE; BREATHING EXERCISE; BRONCHOSCOPY; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISINFECTION; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOTRACHEAL INTUBATION; ENTERIC FEEDING; ENTEROBACTERIACEAE; ENVIRONMENTAL SANITATION; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; HAND WASHING; HISTOPATHOLOGY; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; HUMAN; IMMUNIZATION; INFECTION CONTROL; INFECTION PREVENTION; INSTRUMENT STERILIZATION; LEGIONELLA; LEGIONNAIRE DISEASE; LUNG ASPIRATION; LUNG LAVAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; OCCUPATIONAL EXPOSURE; PATIENT POSITIONING; PHYSIOTHERAPY; PNEUMONIA; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PROTECTIVE EQUIPMENT; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; RADIODIAGNOSIS; REVIEW; RISK REDUCTION; SCORING SYSTEM; SCREENING TEST; SPIROMETRY; STAFF TRAINING; STAPHYLOCOCCUS AUREUS; SUPRAVENTRICULAR TACHYCARDIA; SYSTEMATIC REVIEW; TREATMENT DURATION; UNITED KINGDOM; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; GREAT BRITAIN; HUMANS; INFECTION CONTROL; PNEUMONIA, BACTERIAL;

EID: 45749100460     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn162     Document Type: Review

References (333)

1. Gross P, Neu H, Aswapokee P et al. Deaths from nosocomial infections: Experience in a university hospital and a community hospital. Am J Med 1980; 68: 219-23.
2. Leu HS, Kaiser DL, Mori M et al. Hospital-acquired pneumonia. Attributable mortality and morbidity. Am J Epidemiol 1989; 129 1258-67.
3. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165: 867-903.
4. Cook DJ, Walter SD, Cook RJ et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998;129:433-40.
5. Department of Health. Going further faster: Implementing the Saving Lives delivery programme. Published May 2006. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicy AndGuidance/ DH_4134547 (10 February 2008, date last accessed).
6. Masterton RG. The place of guidelines in hospital acquired pneumonia. J Hosp Infect 2007; 66: 116-22.
7. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
8. Rello J, Artur J, Baaibar J et al. International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest 2001; 120: 955-70.
9. Collard HR, Saint S, Matthay MA. Prevention of ventilator associated pneumonia: An evidence-based systematic review. Ann Intern Med 2003; 138: 494-501.
10. CDC and the Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health-care-associated pneumonia, 2003. Respir Care 2004; 49: 926-39.
11. SIGN 50: A guideline developers' handbook. Published February 2001, updated May 2004. http://www.sign.ac.uk/guidelines/fulltext/50/ index.html (10 February 2008, date last accessed).
12. Christie CD, Glover AM, Willke MJ et al. Containment of pertussis in the regional pediatric hospital during the Greater Cincinnati epidemic of 1993. Infect Control Hosp Epidemiol 1995; 16: 556-63.
13. Salahuddin N, Zafar A, Sukhyani L et al. Reducing ventilator-associated pneumonia rates through a staff education programme. J Hosp Infect 2004; 57: 223-7.
14. Zack JE, Garrison T, Trovillion E et al. Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia. Crit Care Med 2002; 30: 2407-12.
15. Baxter AD, Allan J, Beddard J et al. Adherence to simple and effective measures reduces the incidence of ventilator-associated pneumonia. Can J Anaesth 2005; 52: 535-41.
16. Macartney KK, Gorelick M, Manning M et al. Nosocomial respiratory syncytial virus infections: The cost-effectiveness and cost-benefit of infection control. Pediatrics 2000; 106: 520-6.
17. Neddleman J, Buerhaus P, Mattke P et al. Nurse-staffing levels and the quality of care in hospitals. N Eng J Med 2002; 346: 1715-22.
18. Marelich GP, Murin S, Battistella F et al. Protocol weaning of mechanical ventilation in medical and surgical patients by respiratory care practitioners and nurses: Effect on weaning time and incidence of ventilator-associated pneumonia. Chest 2000; 118: 459-67.
19. Ibrahim EH, Ward S, Sherman G et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29: 1109-15.
20. Ely EW, Baker AM, Dunagan DP et al. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. N Engl J Med 1996; 335: 1864-9.
21. Kollef MH, Shapiro SD, Silver P et al. A randomized, controlled trial of protocol-directed weaning from mechanical ventilation. Crit Care Med 1997; 25: 567-74.
22. Brook AD, Ahrens TS, Schaiff R et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med 1999; 27: 2609-15.
23. Kress JP, Pohlman AS, O'Connor ME et al. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342: 1471-7.
24. MacIntyre NR, Cook DJ, Ely EW et al. Evidence-based guidelines for weaning and discontinuing ventilatory support: A collective task force facilitated by American College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine. Chest 2001; 120 Suppl 6: 375-95S.
25. Haley RW, Culver DH, White JW. The efficacy of infection surveillance and control programs in preventing nosocomial infections in U.S. hospitals. Am J Epidemiol 1985; 121: 182-205.
26. Pearson ML. Guidelines for preventing health-care-associated pneumonia, 2003. Recommendations of the CDC and the Healthcare Infection Control Practices Advisory Committee. Respir Care 2004; 49: 926-39.
27. Gross PA, Hermogenes AW, Sacks HS et al. The efficacy of influenza vaccine in elderly persons: A meta-analysis and review of the literature. Ann Intern Med 1995; 123: 518-27.
28. Potter J, Stott DJ, Roberts MA et al. Influenza vaccination of healthcare workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997; 175: 1-6.
29. Fedson DS, Kessler HA. A hospital-based influenza immunization program, 1977-1978. Am J Public Health 1983; 73: 442-5.
30. Wilde JA, McMillan JA, Serwint J et al. Effectiveness of influenza vaccine in healthcare professionals: A randomized trial. JAMA 1999; 281: 908-13.
31. Saxen H, Virtanen M. Randomized placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of healthcare workers. Pediatr Infect Dis J 1999; 18: 779-83.
32. Carman WF, Elder AG, Wallace LA et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: A randomised controlled trial. Lancet 2000; 355 93-7.
33. Immunisation Against Infectious Disease 1996 - 'The Green Book' new November 2005 chapters. http://www.dh.gov.uk/en/Publichealth/ Healthprotection/immunisation/Greenbook/DH_4097254 (1 March 2008, date last accessed).
34. Boyce JM, Pittet D, Healthcare Infection Control Practices Advisory Committee; HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HIPAC/SHEA/APIC/ IDSA Hand Hygiene Task Force. Am J Infect Control 2002; 30: S1-46.
35. Pittet D, Hugonnet S, Harbarth S et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 2000; 356: 1307-12.
36. Adams BG, Marrie TJ. Hand carriage of Gram-negative rods may not be transient. J Hyg 1982; 89: 33-46.
37. Adams BG, Marrie TJ. Hand carriage of aerobic Gram-negative rods by healthcare personnel. J Hyg 1982; 89: 23-31.
38. Doebbeling BN, Pfaller MA, Houston AK et al. Removal of nosocomial pathogens from the contaminated glove. Implications for glove reuse and handwashing. Ann Intern Med 1988; 109: 394-8.
39. Department of Health and the Hospital Infection Society. The epic Project: Developing National Evidence-based Guidelines for Preventing Healthcare Associated Infections - Standard Principles for preventing hospital-acquired infections. J Hosp Infect 2001; 47 Suppl: S3-82.
40. Garner JS, Healthcare Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17: 53-80.
41. Wake D, Bowry AC, Crook B et al. Performance of respirator filters and surgical masks against bacterial aerosols. J Aerosol Sci 1997; 28: 1311-29.
42. Health and Safety Executive. Personal Protective Equipment at Work Regulations 1992. Guidance on Regulations L25. London: HSE Books, 1992, ISBN 0717604152.
43. Health and Safety Executive. Personal Protective Equipment at Work Regulations 2002. London: HSE Books, 2002.
44. The Control of Substances Hazardous to Health Regulations 2002. Statutory Instruments 2002; London: HM Stationery Office. No. 2677 ISBN: 0110429192.
45. Doebbeling BN, Pfaller MA, Houston AK et al. Removal of nosocomial pathogens from the contaminated glove. Implications for glove reuse and handwashing. Ann Intern Med 1988; 109: 394-8.
46. Medical Devices Agency. DB 2006(04) Single-use Medical Devices: Implications and Consequences of Reuse. http://www.mhra.gov.uk/ Publications/Safetyguidance/DeviceBulletins/CON2024995 (1 March 2008, date last accessed).
47. Hess DR. Evidence based clinical practice guidelines; Care of the ventilator circuit and its relation to ventilator-associated pneumonia. Respir Care 2003; 48: 869-79.
48. Dodek P, Keenan S, Cook D et al. Evidence-based clinical practice guideline for the prevention of ventilator-associated pneumonia. Ann Intern Med 2004; 141: 305-13.
49. Kollef MH, Prentice D, Shapiro SD et al. Mechanical ventilation with or without 7-day circuit changes. A randomized controlled trial. Ann Intern Med 1995; 123: 168-74.
50. Dreyfuss D. Prospective study of nosocomial pneumonia and of patient and circuit colonization during mechanical ventilation with circuit changes every 48 hours versus no change. Am Rev Respir Dis 1991; 143 738-43.
51. Long MN, Wickstom G, Grimes A et al. Prospective, randomized study of ventilator-associated pneumonia in patients with one versus three ventilator circuit changes per week. Infect Control Hosp Epidemiol 1996; 17: 14-9.
52. Lorente L, Lecuona M, Galvan R et al. Periodically changing ventilator circuits is not necessary to prevent ventilator-associated pneumonia when a heat and moisture exchanger is used. Infect Control Hosp Epidemiol 2004; 25: 1077-82.
53. Hubmayr RD. Statement of the 4th International consensus conference in critical care on ICU-acquired pneumonia - Chicago, Illinois, May 2002. Intensive Care Med 2002; 28: 1521-36.
54. Kola A, Eckmanns T, Gastmeier P. Efficacy of heat and moisture exchangers in preventing ventilator-associated pneumonia: Meta-analysis of randomized controlled trials. Intensive Care Med 2005; 31 5-11.
55. Martin C, Perrin G, Gevaudan MJ et al. Heat and moisture exchangers and vaporizing humidifiers in the intensive care unit. Chest 1990; 97: 144-9.
56. Roustan JP, Kienlen J, Aubas P et al. Comparison of hydrophobic heat and moisture exchangers with heated humidifier during prolonged mechanical ventilation. Intensive Care Med 1992; 18: 97-100.
57. Kollef MH, Shapiro SD, Boyd V et al. A randomized clinical trial comparing an extended-use hygroscopic condenser humidifier with heated-water humidification in mechanically ventilated patients. Chest 1998; 113: 759-67.
58. Kirton OC, DeHaven B, Morgan J et al. A prospective, randomized comparison of an in-line heat moisture exchange filter and heated wire humidifiers: Rates of ventilator-associated early-onset (community-acquired) or late-onset (hospital-acquired) pneumonia and incidence of endotracheal tube occlusion. Chest 1997; 112: 1055-9.
59. Boots RJ, Howe S, George N. Clinical utility of hygroscopic heat and moisture exchangers in intensive care patients. Crit Care Med 1997; 25: 1707-12.
60. Dreyfuss D. Mechanical ventilation with heated humidifiers or heat and moisture exchangers: Effects on patient colonization and incidence of nosocomial pneumonia. Am J Respir Crit Care Med 1995; 151: 986-92.
61. Memish ZA, Oni GA, Djazmati W et al. A randomized clinical trial to compare the effects of a heat and moisture exchanger with a heated humidifying system on the occurrence rate of ventilator-associated pneumonia. Am J Infect Control 2001; 29: 301-5.
62. Branson RD, Davis K Jr, Brown R et al. Comparison of three humidification techniques during mechanical ventilation: Patient selection, cost and infection considerations. Respir Care 1996; 41: 809-16.
63. Hurni JM, Feihl F, Lazor R et al. Safety of combined heat and moisture exchanger filters in long-term mechanical ventilation. Chest 1997; 111: 686-91.
64. Markowicz P, Ricard J-D, Dreyfuss D et al. Safety, efficacy, and cost-effectiveness of mechanical ventilation with humidifying filters changed every 48 hours: A prospective, randomized study. Crit Care Med 2000; 28: 665-71.
65. Davis K Jr, Evans SL, Campbell RS et al. Prolonged use of heat and moisture exchangers does not affect device efficiency or frequency rate of nosocomial pneumonia. Crit Care Med 2000; 28: 1412-8.
66. Thomachot L, Leone M, Razzouk K et al. Randomized clinical trial of extended use of a hydrophobic condenser humidifier: 1 vs 7 days. Crit Care Med 2002; 30: 232-7.
67. Mastro TD, Fields BS, Breiman RF et al. Nosocomial Legionnaires' disease and use of medication nebulizers. J Infect Dis 1991; 163: 667-71.
68. Craven DE, Lichtenberg DA, Goularte TA et al. Contaminated medication nebulizers in mechanical ventilator circuits. Source of bacterial aerosols. Am J Med 1984; 77: 834-8.
69. Mertz JJ, Scharer L, McClement JH. A hospital outbreak of Klebsiella pneumonia from inhalation therapy with contaminated aerosol solutions. Am Rev Respir Dis 1967; 95: 454-60.
70. Luttropp HH, Berntman L. Bacterial filters protect anaesthetic equipment in a low-flow system. Anaesthesia 1993; 48: 520-3.
71. Berry AJ, Nolte FS. An alternative strategy for infection control of anesthesia breathing circuits: A laboratory assessment of the Pall HME Filter. Anesth Analg 1991; 72: 651-5.
72. Kollef MH, Prentice D, Shapiro SD et al. Mechanical ventilation with or without daily changes of in-line suction catheters. Am J Respir Crit Care Med 1997; 156: 466-72.
73. Darvas JA, Hawkins LG. The closed tracheal suction catheter: 24 hour or 48 hour change? Aust Crit Care 2003; 16: 86-92.
74. Stoller JK, Orens DK, Fatica C et al. Weekly versus daily changes of in-line suction catheters: Impact on rates of ventilator-associated pneumonia and associated costs. Respir Care 2003; 48: 494-9.
75. Weber DJ, Wilson MB, Rutala WA et al. Manual ventilation bags as a source for bacterial colonization of intubated patients. Am Rev Respir Dis 1990; 142: 892-4.
76. Stone JW, Das BC. Investigation of an outbreak of infection with Acinetobacter calcoaceticus in a special care baby unit. J Hosp Infect 1986; 7: 42-8.
77. Thompson AC, Wilder BJ, Powner DJ. Bedside resuscitation bags: A source of bacterial contamination. Infect Control 1985; 6: 231-2.
78. Fierer J, Taylor PM, Gezon HM. Pseudomonas aeruginosa epidemic traced to delivery-room resuscitators. N Engl J Med 1967; 276 991-6.
79. du Moulin GC, Sauberman AJ. The anesthesia machine and circle system are not likely to be sources of bacterial contamination. Anesthesiology 1977; 47: 353-8.
80. Cunha BA, Klimek JJ, Gracewski J et al. A common source outbreak of Acinetobacter pulmonary infections traced to Wright respirometers. Postgrad Med J 1980; 56: 169-72.
81. Irwin RS, Demers RR, Pratter MR. An outbreak of acinetobacter infection associated with the use of a ventilator spirometer. Respir Care 1980; 25: 232-7.
82. Rutala DR, Rutala WA, Weber DJ et al. Infection risks associated with spirometry. Infect Control Hosp Epidemiol 1991; 12: 89-92.
83. Deppe SA, Kelly JW, Thoi LL et al. Incidence of colonization, nosocomial pneumonia, and mortality in critically ill patients using a Trach Care closed-suction system versus an open-suction system: prospective, randomized study. Crit Care Med 1990; 18: 1389-93.
84. Combes P, Fauvage B, Oleyer C. Nosocomial pneumonia in mechanically ventilated patients, a prospective randomised evaluation of the Stericath closed suctioning system. Intensive Care Med 2000; 26 878-82.
85. Johnson KL, Kearney PA, Johnson SB. Closed versus open endotracheal suctioning: Costs and physiologic consequences. Crit Care Med 1994; 22: 658-66.
86. Zeitoun SS, de Barros AL, Diccini S et al. Incidence of ventilator-associated pneumonia in patients using open-suction systems and closed-suction systems: A prospective study - preliminary data. Rev Lat Am Enfermagem 2001; 9: 46-52.
87. Topeli A, Harmanci A, Cetinkaya Y et al. Comparison of the effect of closed versus open endotracheal suction systems on the development of ventilator associated pneumonia. J Hosp Infect 2004; 58: 14-9.
88. Lorente L, Lecuona M, Martin MM et al. Ventilator-associated pneumonia using a closed versus an open tracheal suction system. Crit Care Med 2005; 33: 115-9.
89. Burns KEA, Adhikari NKJ, Meade MO. Noninvasive positive pressure ventilation as a weaning strategy for intubated adults with respiratory failure (Review). Cochrane Collab 2005; 3: 1-26.
90. Holzapfel L, Chevret S, Madinier G et al. Influence of long-term oro- or nasotracheal intubation on nosocomial maxillary sinusitis and pneumonia: Results of a prospective, randomized, clinical trial. Crit Care Med 1993; 21: 1132-8.
91. Rouby JJ, Laurent P, Gosnach M et al. Risk factors and clinical relevance of nosocomial maxillary sinusitis in the critically ill. Am J Respir Crit Care Med 1994; 150: 776-83.
92. Salord F, Gaussorgues P, Marti-Flich J et al. Nosocomial maxillary sinusitis during mechanical ventilation: A prospective comparison of orotracheal versus the nasotracheal route for intubation. Intensive Care Med 1990; 16: 390-3.
93. Michelson A, Kamp HD, Schuster B. Sinusitis in long-term intubated, intensive care patients: Nasal versus oral intubation. Anaesthesist 1991; 40: 100-4.
94. Bach A, Boehrer H, Schmidt H et al. Nosocomial sinusitis in ventilated patients. Nasotracheal versus orotracheal intubation. Anaesthesia 1992; 47: 335-9.
95. Torres A, Gatell JM, Aznar E et al. Re-intubation increases the risk of nosocomial pneumonia in patients needing mechanical ventilation. Am J Crit Care Med 1995: 152: 137-41.
96. Treloar DM, Stechmiller J. Pulmonary aspiration in tube-fed patients with artificial airways. Heart Lung 1984; 13: 667-71.
97. Bonten MJM, Gaillard VA, van der Hulst R et al. Intermittent enteral feeding: The influence of respiratory and digestive tract colonization in mechanically ventilated intensive-care-unit patients. Am J Respir Crit Care Med 1996; 154: 394-9.
98. Heyland DK, Drover JW, Dhaliwal R et al. Optimizing the benefits and minimizing the risks of enteral nutrition in the critically ill: role of small bowel feeding. J Parenter Enteral Nutr 2002; 26 S51-5.
99. Marik PE, Zaloga GP. Gastric versus post-pyloric feeding: A systematic review. Crit Care 2003; 7: 46-51.
100. Delfuzian C, Shojania K, Collard HR et al. Subglottic secretion drainage for preventing ventilator-associated pneumonia: A meta-analysis. Am J Med 2005; 118: 11-8.
101. Rello J, Sonora R, Jubert P et al. Pneumonia in intubated patients: Role of respiratory airways care. Am J Respir Crit Care Med 1996; 154: 111-5.
102. Messori A, Trippoli S, Vaiani M et al. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: Meta-analysis of randomised controlled trials. BMJ 2000; 321: 1103-6.
103. Tryba. M, Cook DJ. Gastric alkalinization, pneumonia, and systemic infections: The controversy. Scand J Gastroenterol 1995; 210 53-9.
104. Cook DJ. Stress ulcer prophylaxis: Gastrointestinal bleeding and nosocomial pneumonia. Best evidence synthesis. Scand J Gastroenterol Suppl 1995; 210: 48-52.
105. Tryba M. Sucralfate versus antacids or H2-antagonists for stress ulcer prophylaxis: A meta-analysis on efficacy and pneumonia rate. Crit Care Med 1991; 19: 942-9.
106. Cook DJ, Reeve BK, Guyatt GH et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA 1996; 275: 308-14.
107. Tryba M. Prophylaxis of stress-ulcer bleeding. A meta-analysis. J Clin Gastroenterol 1991; 13 Suppl 2: S44-55.
108. Cook DJ, Laine LA, Guyatt GH et al. TA. Nosocomial pneumonia and the role of gastric pH. A meta-analysis. Chest 1991; 100: 7-13.
109. Cook D, Guyatt G, Marshall J et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med 1998; 338: 791-7.
110. Roukema JA, Carole EJ, Prins JG. The prevention of pulmonary complications after upper abdominal surgery in patients with non-compromised pulmonary status. Arch Surg 1988; 123: 30-4.
111. Vraciu JK, Vraciu RA. Effectiveness of breathing exercises in preventing pulmonary complications following open heart surgery. Phys Ther 1977; 57: 1367-71.
112. Celli BR, Rodriguez KS, Snider GL. A controlled trial of intermittent positive pressure breathing, incentive spirometry, and deep breathing exercises in preventing pulmonary complications after abdominal surgery. Am Rev Respir Dis 1984; 130: 12-5.
113. Hall JC, Tarala RA, Tapper J et al. Prevention of respiratory complications after abdominal surgery: A randomised clinical trial. BMJ 1996; 312: 148-52.
114. Ntoumenopoulos G, Presneill JJ, McElholum M et al. Chest physiotherapy for the prevention of ventilator-associated pneumonia. Intensive Care Med 2002; 28: 850-6.
115. Hall JC, Tarala R, Harris J et al. Incentive spirometry versus routine chest physiotherapy for prevention of pulmonary complications after abdominal surgery. Lancet 1991; 337: 953-6.
116. Stoller JK. Are respiratory therapists effective? Assessing the evidence Respir Care 2001; 46: 56-66.
117. Drakulovic MB, Torres A, Bauer TT et al. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: A randomised trial. Lancet 1999; 354: 1851-8.
118. Torres A, Serra-Batlles J, Ros E et al. Pulmonary aspiration of gastric contents in patients receiving mechanical ventilation: The effect of body position. Ann Intern Med 1992; 116: 540-3.
119. Guerin C, Gaillard S, Lemasson S et al. Effects of systematic prone positioning in hypoxemic acute respiratory failure. A randomized controlled trial. JAMA 2004; 292: 2379-87.
120. Kollef MH. Ventilator-associated pneumonia. A multivariate analysis. JAMA 1993; 270: 1965-70.
121. Kollef MH, Von Harz B, Prentice D et al. Patient transport from intensive care increases the risk of developing ventilator-associated pneumonia. Chest 1997; 112: 765-73.
122. Choi SC, Nelson LD. Kinetic therapy in critically ill patients. Combined results based on meta-analysis. J Crit Care 1992; 7: 57-62.
123. Leal-Noval SR, Rincón-Ferrari MD, Garcia-Curiel A et al. Transfusion of blood components and postoperative infection in patients undergoing cardiac surgery. Chest 2001; 119: 1461-8.
124. Vamvakas EC, Carven JH. Transfusion and postoperative pneumonia in coronary artery bypass graft surgery: Effect of the length of storage of transfused red cells. Transfusion 1999; 39: 701-10.
125. Hébert PC, Wells G, Blajchman MA et al. A multicentre, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340: 409-17.
126. Jensen LS, Kissmeyer-Nielsen P, Wolff B et al. Randomised comparison of leucocyte-depleted blood versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996; 348: 841-5.
127. Centers for Disease Control and Prevention. Guidelines for preventing health-care-associated pneumonia, 2003: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR 2004; 53 (No RR-3): 6-7.
128. Sub-Committee of the Scientific Advisory Committee of the National Disease Surveillance Centre. National Guidelines for the Prevention of Nosocomial Invasive Aspergillosis During Construction/Renovation Activities, 2002. http://www.ndsc.ie/hpsc/A-Z/Respiratory/ Aspergillosis/Guidance/File,896,en.pdf (1 March 2008, date last accessed).
129. Division of Nosocomial and Occupational Infections Bureau of Infectious Diseases Centre for Infectious Disease Prevention and Control Population and Public Health Branch Health Canada. Construction-Related Nosocomial Infections in Patients in Healthcare Facilities - Decreasing the Risk of Aspergillus, Legionella and Other Infections. Canada Communicable Disease Report 2001; 2752. http://www.phac-aspc.gc.ca/ publicat/ccdr-rmtc/01pdf/27s2e.pdf (10 February 2008, date last accessed).
130. Streifel AJ, Vesley D, Rhame FS et al. Control of airborne fungal spores in a university hospital. Environ Int 1989; 15: 221-7.
131. Iwen PC, Davis JC, Reed EC et al. Airborne fungal spore monitoring in a protective environment during hospital construction, and correlation with an outbreak of invasive aspergillosis. Infect Control Hosp Epidemiol 1994; 15: 303-6.
132. Cornet M, Levy V, Fleury L et al. Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol 1999; 20: 508-13.
133. Shields ML, Joyner MV, Lee R. Invasive aspergillosis in immunocompromised patients. BMJ 1990; 301: 1046-7.
134. Morgenstern GR, Prentice AG, Prentice HG et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. UK Multicentre Anti-fungal Prophylaxis Study Group. Br J Haematol 1999: 105: 901-11.
135. Gøstzsche PC, Johansen HK. Routine versus selective anti-fungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev 2005; issue 3: 1-29.
136. Harousseau JL, Dekker AW, Stamatoullas-Bastard A et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000; 44: 1887-93.
137. Glasmacher, Prentice A, Gorschlüter M et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21: 4615-26.
138. Cornely O, Ullman AJ, Karthaus M. Evidence based assessment of primary anti-fungal prophylaxis in patients with haematological malignancies. Blood 2003; 101: 3365-72.
139. Working Party of the British Society for Antimicrobial Chemotherapy. Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation: A review and recommendations. J Antimicrob Chemother 1993; 32: 5-21 [published erratum appears in J Antimicrob Chemother 1993; 32: 925].
140. Stout J E, Lin YS, Goetz AM et al. Controlling Legionella in hospital water systems: Experience with the superheat-and-flush method and copper-silver ionization. Infect Control Hosp Epidemiol 1998; 19: 911-4 [erratum appears in Infect Control Hosp Epidemiol 1999; 20: 302].
141. Zacheus OM, Martikainen PJ. Effect of heat flushing on the concentrations of Legionella pneumophila and other heterotrophic microbes in hot water systems of apartment buildings. Can J Microbiol 1996; 42: 811-8.
142. Mermel LA, Josephson SL, Giorgio CH et al. Association of Legionnaires' disease with construction: Contamination of potable water? Infect Control Hosp Epidemiol 1995; 16: 76-81.
143. Liu WK, Healing DE, Yeomans JT et al. Monitoring of hospital water supplies for Legionella. J Hosp Infect 1993; 24: 1-9.
144. Liu Z, Stout JE, Boldin M et al. Intermittent use of copper-silver ionization for Legionella control in water distribution systems: A potential option in buildings housing individuals at low risk of infection. Clin Infect Dis 1998; 26: 138-40.
145. Farrell ID, Barker JE, Miles EP et al. A field study of the survival of Legionella pneumophila in a hospital hot-water system. Epidemiol Infect 1990; 104: 381-7.
146. Edelstein PH, Whittaker RE, Kreiling RL et al. Efficacy of ozone in eradication of Legionella pneumophila from hospital plumbing fixtures. Appl Environ Microbiol 1982; 44: 1330-4.
147. Mietzner S, Schwille RC, Farley A et al. Efficacy of thermal treatment and copper-silver ionization for controlling Legionella pneumophila in high-volume hot water plumbing systems in hospitals. Am J Infect Control 1997; 25: 452-7 [erratum appears in Am J Infect Control 1998; 26: 112].
148. Ezzeddine H, Van Ossell C, Delmee M et al. Legionella spp. in a hospital hot water system: Effect of control measures. J Hosp Infect 1989; 13: 121-31.
149. Hamilton E, Seal DV, Hay J. Comparison of chlorine and chlorine dioxide disinfection for control of Legionella in a hospital potable water supply. J Hosp Infect 1996; 32: 156-60.
150. Department of Health. Estates and Facilities Division. Water systems: Health Technical Memorandum 04-01 Water systems: The control of Legionella, hygiene, 'safe' hot water, cold water and drinking water systems. Part A: Design, installation and testing. London, 2006. http://www.estatesknowledge.dh.gov.uk (1 March 2008, date last accessed).
151. Department of Health. Estates and Facilities Division. Water systems: Health Technical Memorandum 04-01 Water systems: The control of Legionella, hygiene, 'safe' hot water, cold water and drinking water systems. Part B: Operational management. London, 2006. http://www.estatesknowledge.dh.gov.uk (1 March 2008, date last accessed).
152. O'Neill E, Humphreys H. Surveillance of hospital water and primary prevention of nosocomial legionellosis: What is the evidence? J Hosp Infect 2005; 59: 273-9.
153. Dancer SJ. How do we assess hospital cleaning? A proposal for microbiological standards for surface hygiene in hospitals. J Hosp Infect 2004; 56: 10-5.
154. Gillespie TA, Johnson PR, Notman AW et al. Eradication of a resistant Pseudomonas aeruginosa strain after a cluster of infections in a hematology/oncology unit. Clin Microbiol Infect 2000; 6: 125-30.
155. Healthcare Associated Infection Task Force. The NHS Scotland National Cleaning Services Specification, 2004. http://www.scotland.gov.uk/ library5/health/ncss.pdf (10 February 2008, date last accessed).
156. Department of Health - NHS Estates. Revised Guidance on Contracting for Cleaning, 2004. http://www.dh.gov.uk/assetRoot/04/09/75/37/ 04097537.pdf (10 February 2008, date last accessed).
157. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement. Am J Respir Crit Care Med 1995; 153: 1711-25.
158. Craven DE, Steger K. Epidemiology of nosocomial pneumonia: New perspectives on an old disease. Chest 1995; 108: 1-16S.
159. Grossman RF, Fain A. Evidence-based assessment of diagnostic tests for ventilator-associated pneumonia: Executive summary. Chest 2000; 117: 177-81S.
160. Mayhall CG. Ventilator-associated pneumonia or not? Contemporary diagnosis. Emerg Infect Dis 2001; 7: 200-4.
161. Wunderink RG. Clinical criteria in the diagnosis of ventilator-associated pneumonia. Chest 2000; 117 Suppl 2: 191-4S.
162. Johanson WG, Seidenfeld JJ, Gomez P et al. Bacteriologic diagnosis of nosocomial pneumonia following prolonged mechanical ventilation. Am Rev Respir Dis 1988; 137: 259-64.
163. Corley DE, Kirtland SH, Winterbauer RH et al. Reproducibility of the histologic diagnosis of pneumonia among a panel of four pathologists. Analysis of a gold standard. Chest 1997; 112: 458-65.
164. Wermert D, Marquette CH, Copin MC et al. Influence of pulmonary bacteriology and histology on the yield of diagnostic procedures in ventilator-acquired pneumonia. Am J Respir Crit Care Med 1998; 158: 139-47.
165. Rouby JJ, Rossignon MD, Nicolas MH et al. A prospective study of protected bronchoalveolar lavage in the diagnosis of nosocomial pneumonia. Anesthesiology 1989; 71: 679-85.
166. Marquette CH, Copin MC, Wallet F et al. Diagnostic tests for pneumonia in ventilated patients: Prospective evaluation of diagnostic accuracy using histology as a diagnostic gold standard. Am J Respir Crit Care Med 1995; 151: 1878-88.
167. Marquette CH, Wallet F, Copin MC et al. Relationship between microbiologic and histologic features in bacterial pneumonia. Am J Respir Crit Care Med 1996; 154: 1784-87.
168. Pingleton SK, Fagon JY, Leeper KV Jr. Patient selection for clinical investigation of ventilator-associated pneumonia. Criteria for evaluating diagnostic techniques. Chest 1992; 102 Suppl 1: 553-6S.
169. Fartoukh M, Maitre B, Honoré S et al. Diagnosing pneumonia during mechanical ventilation: The clinical pulmonary infection score revisited. Am J Respir Crit Care Med 2003; 168: 173-9.
170. Torres A, Carlet J. European task force on ventilator-associated pneumonia. Eur Respir J 2001; 17: 1034-45.
171. Bone RC, Sprung CL, Sibbald WJ. Definitions for sepsis and organ failure. Crit Care Med 1992; 20: 724-6.
172. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29: 530-8.
173. Kirtland SH, Corley DE, Winterbaur RH et al. The diagnosis of ventilator-associated pneumonia: A comparison of histologic, microbiologic, and clinical criteria. Chest 1997; 112: 445-57.
174. Pugin J, Auckenthaler R, Mili N et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and non-bronchoscopic 'blind' bronchoalveolar lavage fluid. Am Rev Respir Dis 1991; 143: 1121-9.
175. Pugin J. Clinical signs and scores for the diagnosis of ventilator-associated pneumonia. Minerva Anestesiol 2002; 68 261-5.
176. Fàbregas N, Ewig S, Torres A et al. Clinical diagnosis of ventilator associated pneumonia revisited: Comparative validation using immediate post-mortem lung biopsies. Thorax 1999; 54: 867-73.
177. Luna CM, Blanzaco D, Niederman MS et al. Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003; 31: 676-82.
178. Singh N, Rogers P, Atwood CW et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162: 565-11.
179. Wunderink RG. Radiologic diagnosis of ventilator-associated pneumonia. Chest 2000; 117 Suppl 2: 188-90S.
180. San Pedro G. Are quantitative cultures useful in the diagnosis of hospital-acquired pneumonia? Chest 2001; 119 Suppl 2: 385-90S.
181. Garrard CS, A'Court CD. The diagnosis of pneumonia in the critically ill. Chest 1995; 108 Suppl 2: 17-25S.
182. Meduri GU, Chastre J. The standardization of bronchoscopic techniques for ventilator-associated pneumonia. Chest 1992; 102 Suppl 1: 557-64S.
183. Bergogne-Berezin E. Treatment and prevention of nosocomial pneumonia. Chest 1995; 108: 26-34.
184. Richards MJ, Edwards JR, Culver DH et al. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27: 887-92.
185. Vincent JL, Bihari DJ, Suter PM et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274: 639-44.
186. Montravers P, Veber B, Auboyer C et al. Diagnostic and therapeutic management of nosocomial pneumonia in surgical patients: Results of the Eole study. Crit Care Med 2002; 30: 368-75.
187. Ibrahim EH, Ward S, Sherman G et al. A comparative analysis of patients with early onset vs late-onset nosocomial pneumonia in the ICU setting. Chest 2000; 117: 1434-42.
188. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134: 298-314.
189. Fridkin SK. Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med 2001; 29 Suppl 4: N64-8.
190. Trouillet JL, Chastre J, Vuagnat A et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157: 531-9.
191. Bochicchio GV, Joshi M, Bochicchio K et al. A time-dependent analysis of intensive care unit pneumonia in trauma patients. J Trauma 2004; 56: 296-303.
192. Rello J, Sa-Borges M, Correa H et al. Variations in etiology of ventilator associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999; 160: 608-13.
193. Luna CM, Videla A, Mattera J et al. Blood cultures have limited value in predicting severity of illness and as a diagnostic tool in ventilator-associated pneumonia. Chest 1999; 116: 1075-84.
194. Baughman RP. Protected-specimen brush technique in the diagnosis of ventilator associated pneumonia. Chest 2000; 117 Suppl 2: 203-6S.
195. Torres A, El-Ebiary M. Bronchoscopic BAL in the diagnosis of ventilator-associated pneumonia. Chest 2000; 117 Suppl 2: 198-202S.
196. de Jaeger A, Litalien C, Lacroix J et al. Protected specimen brush or bronchoalveolar lavage to diagnose bacterial nosocomial pneumonia in ventilated adults: A meta-analysis. Crit Care Med 1999; 27: 2548-60.
197. Campbell GD Jr. Blinded invasive diagnostic procedures in ventilator-associated pneumonia. Chest 2000; 117 Suppl 2: 207-11S.
198. Timsit JE, Cheval C, Gachot B et al. Usefulness of a strategy based on bronchoscopy with direct examination of bronchoalveolar lavage fluids in the initial antibiotic therapy of suspected ventilator-associated pneumonia. Intensive Care Med 2001; 27 640-7.
199. Wood AY, Davit AJ, Ciraulo DL et al. A prospective assessment of diagnostic efficacy of blind protective bronchial brushings compared to bronchoscope-assisted lavage, bronchoscope-directed brushings, and blind endotracheal aspirates in ventilator-associated pneumonia. J Trauma 2003; 55: 825-34.
200. Cook D, Mandell L. Endotracheal aspiration in the diagnosis of ventilator associated pneumonia. Chest 2000; 117 Suppl 2: 195-7S.
201. Mentec H, May-Michelangeli L, Rabbat A et al. Blind and bronchoscopic sampling methods in suspected ventilator-associated pneumonia. Intensive Care Med 2004; 30: 1319-26.
202. Brasel KJ, Allen B, Edmiston C et al. Correlation of intracellular organisms with quantitative endotracheal aspirate. J Trauma 2003: 54: 141-6.
203. Baughman RP. Diagnosis of ventilator-associated pneumonia. Curr Opin Crit Care 2003; 9: 397-4022.
204. Ewig S, Torres A. Prevention and management of ventilator-associated pneumonia. Curr Opin Crit Care 2002; 8: 58-69.
205. Gerbeaux P, Ledoray V, Boussuges A et al. Diagnosis of nosocomial pneumonia in mechanically ventilated patients. Am J Crit Care Med 1998; 157: 76-80.
206. Butler KL, Best IM, Oster RA et al. Is bilateral protected specimen brush sampling necessary for the accurate diagnosis of ventilator-associated pneumonia? J Trauma 2004; 57: 316-22.
207. Sirvent J-M, Vidaur L, Gonzalez S et al. Microscopic examination of intracellular organisms in protected bronchoalveolar mini-lavage fluid for the diagnosis of ventilator-associated pneumonia. Chest 2003; 123: 518-23.
208. Nathens AB, Marshall JC. Selective decontamination of the digestive tract in surgical patients: A systematic review of the evidence. Arch Surg 1999; 134: 170-6.
209. D'Amico R, Pifferi S, Leonetti C et al. Effectiveness of antibiotic prophylaxis in critically ill adult patients: Systematic review of randomised controlled trials. BMJ 1998; 316: 1275-85.
210. Kollef MH. The role of selective digestive tract decontamination on mortality and respiratory tract infections. A meta-analysis. Chest 1994; 105: 1101-8.
211. Liberati A, D'Amico R, Pifferi et al. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database Syst Rev 2004; issue 1: CDO00022 (DOI: 10.1002/14651858.CD000022.pub2).
212. van Nieuwenhoven CA, Buskens E, van Tiel FH et al. Relationship between methodological trial quality and the effects of selective digestive decontamination on pneumonia and mortality in critically ill patients. JAMA 2001; 286: 335-40.
213. de Jonge E, Schultz MJ, Spanjaard L et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: A randomised controlled trial. Lancet 2003; 362: 1011-16.
214. Nardi G, Di Silvestro AD, De Monte A et al. Reduction in Gram-positive pneumonia and antibiotic consumption following the use of a SDD protocol including nasal and oral mupirocin. Eur J Emerg Med 2001; 8: 203-14.
215. Lingnau W, Berger J, Javorsky F et al. Changing bacterial ecology during a five year period of selective intestinal decontamination. J Hosp Infect 1998; 39: 195-206.
216. Sanchez GM, Cambronero Galache JA, Lopez DJ et al. Effectiveness and cost of selective decontamination of the digestive tract in critically ill intubated patients. A randomized, double-blind, placebo-controlled, multicenter trial. Am J Respir Crit Care Med 1998; 158: 908-16.
217. Krueger WA, Lenhart FP, Neeser G et al. Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions and mortality in critically ill surgical patients: A prospective, stratified, randomised, doubleblind, placebo-controlled clinical trial. Am J Respir Crit Care Med 2002; 166: 1029-37.
218. Filos KS. Selective decontamination of the digestive tract: Implications for the critically ill patient. A critical review. Arch Hellenic Med 2003; 20 Suppl A: 78-86.
219. Rocha LA, Martin MJ, Pita S et al. Prevention of nosocomial infection in critically ill patients by selective decontamination of the digestive tract. A randomized, double blind, placebo-controlled study. Intensive Care Med 1992; 18: 398-404.
220. Korinek AM, Laisne MJ, Nicolas MH et al. Selective decontamination of the digestive tract in neurosurgical intensive care unit patients: A double-blind, randomized, placebo-controlled study. Crit Care Med 1993; 21: 1466-73.
221. Stoutenbeek CP, van Saene HKF, Zandstra DF. Prevention of multiple organ system failure by selective decontamination of the digestive tract in multiple trauma patients. In: Faist E, Baue AE, Schildberg FW eds. Immune Consequences of Trauma, Shock and Sepsis. Lengerich: Pabst Science Publishers, 1996; 1055-66.
222. Sirvent JM, Torres A, El-Ebiary M et al. Protective effect of intravenously administered cefuroxime against nosocomial pneumonia in patients with structural coma. Am J Respir Crit Care Med 1997; 155: 1729-34.
223. Kimura A, Mochizuki T, Nishizawa K et al. Trimethoprim-sulfamethoxazole for the prevention of meticillin-resistant Staphylococcus aureus pneumonia in severely burned patients. J Trauma 1998; 45: 383-7.
224. Acquarolo A, Urli T, Perone G et al. Antibiotic prophylaxis of early onset pneumonia in critically ill comatose patients. A randomized study. Intensive Care Med 2005; 31: 510-6.
225. Wunderink RG, Rello J, Cammarata SK et al. Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-97.
226. Rubinstein E, Cammarata S, Oliphant T et al. Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32: 402-12.
227. Norrby SR, Petermann W, Willcox PA et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998; 30: 397-404.
228. Wolff M. Comparison of strategies using cefpirome and ceftazidime for empiric treatment of pneumonia in intensive care patients. Antimicrob Agents Chemother 1998; 42: 28-36.
229. Rodloff AG, Laubenthal HJ, Bastian A et al. Comparative study of the cost-/effectiveness relationship of initial therapy with imipenem/ cilastatin in nosocomial pneumonia [German], Anasthesiol Intensivmed Notfallmed Schmerzther 1996; 31: 172-80.
230. Fink MP, Snydman DR, Niederman MS et al. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, doubleblind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994; 38: 547-57.
231. Wunderink RG, Cammarata SK, Oliphant TH et al. Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25: 980-92.
232. Cepeda JA, Whitehouse T, Cooper B et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: A randomized, doubleblind, multicentre study. J Antimicrob Chemother 2004; 53: 345-55.
233. Le Conte G, Potel E, Clementi A et al. Administration of tobramycin aerosols in patients with nosocomial pneumonia: A preliminary study. Presse Med 2000; 29: 76-8.
234. Georges B, Archambaud M, Saivin S et al. Continuous versus intermittent cefepime infusion in critical care patients. Preliminary findings. Pathol Biol 1999; 47: 483-5.
235. Cone LA, Woodard DR, Stoltzman DS et al. Ceftazidime versus treatment of pneumonia and bacteremia. Antimicrob Agents Chemother 1985; 28: 33-6.
236. Torres A, de Celis R, Rabinad E et al. Therapeutic efficacy of the combination of aztreonam with cefotaxime in the treatment of severe nosocomial pneumonia. Comparative study against amikacin combined with cefotaxime. Chemotherapy 1989; 35 Suppl 1: 15-24.
237. Rapp RP, Billeter M, Hatton J et al. Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection. Clin Pharm 1991; 10: 49-55.
238. Gao DW, Liu CL, Zhang JC. Observation of the therapeutic effect of cefepime in the treatment of nosocomial pneumonia. Chin Pharm J 1999; 34: 624-6.
239. Rapp RP, Young B, Foster TS et al. Ceftazidime versus tobramycin/ ticarcillin in treating hospital acquired pneumonia and bacteremia. Pharmacotherapy 1984; 4: 211-5.
240. Nicolau DP, McNabb J, Lacy MK et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001; 17: 497-504.
241. Heinrich R, Mitschka J. Multi-center, randomised comparative study of ceftazidime vs. cefolaxime in the treatment of patients 65 years of age and older with nosocomial bacterial pulmonary and urinary tract infections. Int J Exp Clin Chemother 1991; 4: 40-7.
242. Hartenauer U, Weilemann LS, Bodmann KF et al. Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias. J Hosp Infect 1990; 15 61-4.
243. Trenholme GM, Schmitt BA, Spear J et al. Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections. Am J Med 1989; 87 Suppl: S116-8.
244. Siami GA, Wilkins WT, Bess DT et al. Comparison of ciprofloxacin with imipenem in the treatment of severe pneumonia in hospitalised geriatric patients. Drugs 1995; 49: 436-8.
245. Schentag JJ, Vari AJ, Winslade NE et al. Treatment with aztreonam or tobramycin in critical care patients with nosocomial Gram-negative pneumonia. Am J Med 1985; 78: 34-41.
246. Villavicencio J, Asensio de Fernandez ME, Ramirez CA et al. Intravenous ciprofloxacin or ceftazidime in selected infections. A prospective, randomized, controlled study. Am J Med 1989; 87 Suppl: 191-4S.
247. Fekete T, Castellano M, Ramirez J et al. A randomised comparative trial of aztreonam plus cefazolin versus ceftazidime for the treatment of nosocomial pneumonia. Drug Invest 1994; 7: 117-26.
248. Bassetti D, Cruciani M, Solbiati M et al. Comparative efficacy of ceftriaxone versus ceftazidime in the treatment of nosocomial lower respiratory tract infections. Chemotherapy 1991; 37: 371-5.
249. Giamarellou H, Mandragos K, Bechrakis P et al. Pefloxacin versus imipenem in the therapy of nosocomial lung infections of intensive care unit patients. J Antimicrob Chemother 1990; 26: 117-27.
250. Nolen TM, Phillips HL, Hall HJ et al. Comparison of aztreonam and tobramycin in the treatment of lower respiratory tract infections caused by Gram-negative bacilli. Rev Infect Dis 1985; 7 Suppl: S666-8.
251. Thomas PD, Daly S, Misan G et al. Comparison of the efficacy and adverse effect profile of cefotaxime, 3 g day-1, and ceftriaxone, 2 g day-1, in the treatment of nosocomial lower respiratory tract infections in ICU patients. Eur Respir Rev 1994; 4: 321-8.
252. Mouton YJ, Beuscart C. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995; 36: 145-56.
253. Bjornson HS, Ramirez-Ronda C, Saavedra S et al. Comparison of empiric aztreonam and aminoglycoside regimens in the treatment of serious Gram-negative lower respiratory infections. Clin Ther 1993; 15: 65-78.
254. Beaucaire G. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia. J Chemother 1995; 7 Suppl 2: 165-73.
255. Rodriguez JR, Ramirez-Ronda CH, Nevarez M. Efficacy and safety of aztreonam versus tobramycin for aerobic Gram-negative bacilli lower respiratory tract infections. Am J Med 1985; 78: 42-3.
256. Mandell LA, Nicolle LE, Ronald AR et al. A multicentre prospective randomized trial comparing ceftazidime with cefazolin/tobramycin in the treatment of hospitalized patients with non-pneumococcal pneumonia. J Antimicrob Chemother 1983; 12: 9-20.
257. Kljucar S. Ceftazidime with and without tobramycin versus azlocillin plus tobramycin in the therapy of bronchopulmonary infections in intensive care patients. Infection 1987; 15 Suppl: S185-91.
258. Warren JW, Miller EH, Jr, Fitzpatrick B et al. A randomized, controlled trial of cefoperazone vs. cefamandole-tobramycin in the treatment of putative, severe infections with Gram-negative bacilli. Rev Infect Dis 1983; 5 Suppl: S173-80.
259. Brown RB, Lemeshow S, Teres D. Moxalactam vs carbenicillin plus tobramycin: Treatment of nosocomial Gram-negative bacillary pneumonias in nonneutropenic patients. Curr Ther Res 1984; 36: 557-64.
260. Fagon J, Patrick H, Haas DW et al. Treatment of Gram positive nosocomial pneumonia: Prospective randomized comparison of quinupristin/ dalfopristin versus vancomycin. Am J Respir Crit Care Med 2000; 161: 753-62.
261. Rivera-Vazquez CR, Ramirez-Ronda CH, Rodriguez JR et al. A comparative analysis of aztreonam + clindamycin versus tobramycin + clindamycin or amikacin + mezlocillin in the treatment of Gram-negative lower respiratory tract infections. Chemotherapy 1989; 35 Suppl 1: 89-100.
262. Giamarellou H, Perdikaris G, Galanakis N et al. Pefloxacin versus ceftazidime in the treatment of a variety of Gram-negative-bacterial infections. Antimicrob Agents Chemother 1989; 33: 1362-7.
263. Beaucaire G, Nicolas MH, Martin C et al. Comparative study of combined cefepime-amikacin versus ceftazidime combined with amikacin in the treatment of nosocomial pneumonias in ventilated patients. Multicenter group study. Ann Fr Anesth Reanim 1999; 18: 186-95.
264. Zanetti G, Bally F, Greub G et al. Cefepime versus imipenemcilastatin for treatment of nosocomial pneumonia in intensive care unit patients: A multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47: 3442-7.
265. Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R et al. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: A prospective randomized multicenter trial. Intensive Care Med 2001; 27: 493-502.
266. Hopkins DW, Daniel R. Trovafloxacin vs ciprofloxacin +/- clindamycin/ metronidazole in patients with nosocomial pneumonia. Drugs 1999; 58: 323-5.
267. Brun-Buisson C, Sollet JP, Schweich H et al. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: A multicenter, randomized controlled trial. VAP Study Group. Clin Infect Dis 1998; 26: 346-54.
268. Jaccard C, Troillet N, Harbarth S et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42: 2966-72.
269. Willis R, Gaines J, Nelson M et al. Cefepime vs cefotaxime in the treatment of pneumonia. Infect Med 1998; 15: 636-43.
270. Saginur R, Garber G, Darling G et al. Prospective, randomized comparison of intravenous and oral ciprofloxacin. Can J Infect Dis 1997; 8: 89-94.
271. Shah PM, Stille W. Cefotaxime versus ceftriaxone for the treatment of nosocomial pneumonia: Results of a multicenter study. Diagn Microbiol Infect Dis 1995; 22: 171-2.
272. Norrby SR, Finch RG, Glauser M. Monotherapy in serious hospital-acquired infections: A clinical trial of ceftazidime versus imipenem/cilastatin. J Antimicrob Chemother 1993; 31: 927-37.
273. Beuscart C, Leroy O, Mouton Y et al. Prospective randomized controlled study of the ceftazidim-pefloxacin combination versus the ceftazidim-amikacin combination in the empirical treatment of pneumonia and nosocomial septicemia in intensive care units. Pathol Biol 1989; 37: 496-9.
274. Cometta A, Baumgartner JD, Lew D et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994; 38: 1309-13.
275. West M, Boulanger BR, Fogarty C et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study. Clin Ther 2003; 25: 485-506.
276. Sieger B, Berman SJ, Geckler RW et al. Empiric treatment of hospital acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: A randomized study. Meropenem Lower Respiratory Infection Group. Crit Care Med 1997; 25: 1663-70.
277. Koehler CO, Arnold H. Controlled clinical study of ceftazidime (3 × 1 g daily) versus piperacillin + tobramycin in patients with nosocomial pneumonia. Int J Exp Clin Chemother 1990; 3: 211-8.
278. Alvarez LF. Efficacy of monotherapy by meropenem in ventilator-associated pneumonia. J Chemother 2001; 13: 70-81.
279. Mandell LA, Nicolle LE, Ronald AR et al. A prospective randomized trial of ceftazidime versus cefazolin/tobramycin in the treatment of hospitalized patients with pneumonia. J Antimicrob Chemother 1987; 20: 95-107.
280. Rubinstein E, Lode H, Grassi C. Ceftazidime monotherapy vs. ceftriaxone/ tobramycin for serious hospital-acquired Gram-negative infections. Antibiotic Study Group. Clin Infect Dis 1995; 20: 1217-28.
281. Mangi RJ, Greco T, Ryan J et al. Cefoperazone versus combination antibiotic therapy of hospital-acquired pneumonia. Am J Med 1988; 84: 68-74.
282. Mangi RJ, Ryan J, Berenson C et al. Cefoperazone versus ceftazidime monotherapy of nosocomial pneumonia. Am J Med 1988; 85: 44-8.
283. Joshi M, Bernstein J, Solomkin J et al. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/ tazobactam Nosocomial Pneumonia Study Group. J Antimicrob Chemother 1994; 43: 389-97.
284. Niederman MS, Torres A, Summer A. Invasive diagnostic testing is not needed routinely to manage suspected ventilator-associated pneumonia. Am J Respir Crit Care Med 1994; 150: 565-9.
285. Chastre J, Fagon J-Y. Invasive diagnostic testing should be routinely used to manage ventilated patients with suspected pneumonia. Am J Respir Crit Care Med 1994; 150: 570-4.
286. Niederman MS. Bronchoscopy for ventilator-associated pneumonia: Show me the money (outcome benefit)! Crit Care Med 1998; 26: 198-9.
287. Croce MA, Fabian TC, Shaw B et al. Analysis of charges associated with diagnosis of nosocomial pneumonia: Can routine bronchoscopy be justified? J Trauma 1994; 37: 721-7.
288. Heyland DK, Cook DJ, Marshall J et al. The clinical utility of invasive diagnostic techniques in the setting of ventilator-associated pneumonia. Chest 1999; 115: 1076-84.
289. Luyt CE, Chastre J, Fagon JY. Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumonia. Intensive Care Med 2004; 30: 844-52.
290. Fagon J-Y, Chastre J, Wolff M et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000; 132: 621-30.
291. Sanchez-Nieto JM, Torres A, Garcia-Cordoba F et al. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia. Am J Respir Crit Care Med 1998; 157: 371-6.
292. Ruiz M, Torres A, Ewig S et al. Noninvasive versus invasive microbiological investigation in VAP. Am J Respir Crit Care Med 2000; 162: 119-25.
293. Solé Violán J, Arroyo Fernandez J, Bordes Benitez A et al. Impact of quantitative invasive techniques in the management and outcome of mechanically ventilated patients with suspected pneumonia. Crit Care Med 2000; 28: 2737-41.
294. Luna CM, Vujacich P, Niederman MS et al. Impact of BAL data on the therapy and outcome of ventilator associated pneumonia. Chest 1997; 111: 676-85.
295. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes. Implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113: 412-20.
296. Kollef MH, Silver P, Murphy DM et al. The effect of late-onset ventilator associated pneumonia in determining patient mortality. Chest 1995; 108: 1655-62.
297. Garnacho J, Sole-Violan J, Sa-Borges M et al. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 2003; 31: 2478-82.
298. Combes A, Luyt C-E, Fagon J-Y et al. Impact of methicillin resistance on outcome of Staphylocoocus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 2004; 170: 786-92.
299. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit: ICU Acquired Pneumonia Study Group. Intensive Care Med 1996; 22: 387-94.
300. Dupont H, Mentec H, Sollet JP et al. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001; 27: 355-62.
301. Kollef MH. Treatment of ventilator-associated pneumonia: Get it right from the start. Crit Care Med 2003; 31: 969-70.
302. Mehta R, Niederman MS. Adequate empirical therapy minimizes the impact of diagnostic methods in patients with ventilator-associated pneumonia. Crit Care Med 2000; 28: 3092-4.
303. Rello J, Gallego M, Mariscal D et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156: 196-200.
304. Iregui M, Ward S, Sherman G et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262-8.
305. Bonten MJ, Bergmans DC, Stobberingh EE et al. Implementation of bronchoscopic techniques in the diagnosis of ventilator-associated pneumonia to reduce antibiotic use. Am J Respir Crit Care Med 1997; 156: 1820-4.
306. Chastre J, Wolff M, Fagon JY, Chevret S et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA 2003; 290: 2588-98.
307. Kollef MH, Rello J, Cammarata SK et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: Retrospective analysis of two doubleblind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30: 388-94.
308. Forrest A, Nix DE, Ballow CH et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-81.
309. Thomas JK, Forrest A, Bhavnani SM et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patents during therapy. Antimicrob Agents Chemother 1998; 42: 521 -7.
310. Kashuba AD, Nafziger AN, Drusano GL et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother 1999; 43: 623-9.
311. Fernandez-Guerrero M, Gudiol F, Rodriguez-Torres A et al. Nosocomial pneumonia: Comparative multicentre trial between monotherapy with cefotaxime and treatment with antibiotic combinations. Infection 1991; 19 Suppl: S320-5.
312. Speich R, Imhof E, Vogt M et al. Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an amino-glycoside in the treatment of severe pneumonia. Eur J Clin Microbiol Infect Dis 1998; 17: 313-7.
313. Paul M, Benuri-Silbiger I, Soares-Weiser K et al. β-Lactam monotherapy versus β-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: Systematic review and meta-analysis of randomised trials. BMJ 2004; 328: 668.
314. Badia JR, Soy D, Adrover M et al. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. J Antimicrob Chemother 2004; 54: 508-14.
315. Palmer LB, Smaldone GC, Simon SR et al. Aerosolized antibiotics in mechanically ventilated patients: Delivery and response. Crit Care Med 1998; 26: 31-9.
316. Bressolle F, de la Coussaye JE, Ayoub R et al. Endotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia: Pharmacokinetics and absolute bioavailability. Antimicrob Agents Chemother 1992; 36: 1404-11.
317. Brown RB, Kruse JA, Counts GW et al. Double-blind study of endotracheal tobramycin in the treatment of Gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group. Antimicrob Agents Chemother 1990; 34: 269-72.
318. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003; issue 3 CD001021 (DOI: 10.1002/14651858.CDO01021).
319. Bassaris HP, Williams Hopkins D, Daniel R. IV-to-oral switch therapy with trovafloxacin compared with IV ceftazidime/oral ciprofloxacin in the treatment of nosocomial pneumonia. Drugs 1999; 58 Suppl 2: 309-11.
320. Solbrig A, Bucher I, Sieber W et al. Comparative study on the clinical efficacy and compatibility of fleroxacin versus ciprofloxacin. Atemwegs-und Lungenkrkh 1996; 22 Suppl: S615-9.
321. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
322. Cheng AC, Stephens DP, Currie BJ. Granulocyte-colony stimulating factor (GCSF) as an adjunct to antibiotics in the treatment of pneumonia in adults (Review). Cochrane Database Syst Rev 2004; CDO04400, doi:10.1002/14651858.CD004400.pub3.
323. Wunderink RG, Leeper KV, Schein R et al. Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest 2001; 119: 523-9.
324. Meyanci G, Oz H. Combination of granulocyte colony-stimulating factor and antibacterial drugs for the treatment of ventilatory associated nosocomial pneumonia. Middle East J Anesthesiol 2001; 16: 91-101.
325. Root RK, Lodato RF, Patrick W et al. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003; 31: 367-73.
326. Hartmann P, Lammertink J, Mansmann G et al. A randomized, placebo controlled study of the use of filgrastim in non neutropenic patients with nosocomial pneumonia. Eur J Med Res 2005; 10: 29-35.
327. Graham WG, Bradley DA. Efficacy of chest physiotherapy and intermittent positive-pressure breathing in the resolution of pneumonia. N Engl J Med 1978; 299: 624-7.
328. Monton C, Ewig S, Torres A et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: A pilot study. Eur Respir J 1999; 14: 218-20.
329. Patterson TF, Patterson JE, Masecar BL et al. A nosocomial outbreak of Branhamella catarrhalis confirmed by restriction endonuclease analysis. J Infect Dis 1988; 157: 996-1001.
330. Barlow G. Pneumonia guidelines in practice. In: Gould I, van der Meer JW eds. Antibiotic Policies: Theory and Practice. New York: Kluwer AGademic/Plenum Publishers, 2005; 37-61.
331. Barlow G, Lamping D, Davey P et al. Evaluating outcomes in community acquired pneumonia: A guide for patients, physicians and policy makers. Lancet Infect Dis 2003; 3: 476-88.
332. Micek ST, Ward S, Fraser VJ et al. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004; 125: 1791-9.
333. Gemmell CG, Edwards DI, Fraise AP et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57: 589-608.